These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 14640050)

  • 1. Drug effects on the kidney.
    Cassidy MJ
    Practitioner; 2003 Nov; 247(1652):874-9. PubMed ID: 14640050
    [No Abstract]   [Full Text] [Related]  

  • 2. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists.
    Berns JS; Kasbekar N
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):117-29. PubMed ID: 17699198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney.
    Campbell GA; Rosner MH
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1852-60. PubMed ID: 18684895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced kidney diseases.
    Singh NP; Ganguli A; Prakash A
    J Assoc Physicians India; 2003 Oct; 51():970-9. PubMed ID: 14719587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs and the kidney.
    Aronoff GR
    Curr Opin Nephrol Hypertens; 1993 Mar; 2(2):187-91. PubMed ID: 7922176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal function and pharmacotherapy in children].
    Jovanović O
    Srp Arh Celok Lek; 1995 Jun; 123 Suppl 1():15-21. PubMed ID: 18193796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats.
    Mohan IK; Khan M; Shobha JC; Naidu MU; Prayag A; Kuppusamy P; Kutala VK
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):802-8. PubMed ID: 16552571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection.
    Perico N; Benigni A; Remuzzi G
    Nat Rev Drug Discov; 2008 Nov; 7(11):936-53. PubMed ID: 18846102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low renal toxicity of lipoplatin compared to cisplatin in animals.
    Devarajan P; Tarabishi R; Mishra J; Ma Q; Kourvetaris A; Vougiouka M; Boulikas T
    Anticancer Res; 2004; 24(4):2193-200. PubMed ID: 15330160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging evidence of the impact of kidney disease on drug metabolism and transport.
    Nolin TD; Naud J; Leblond FA; Pichette V
    Clin Pharmacol Ther; 2008 Jun; 83(6):898-903. PubMed ID: 18388866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of N-acetylcysteine on methotrexate-induced oxidative renal damage in rats.
    Cetinkaya A; Kurutas EB; Bulbuloglu E; Kantarceken B
    Nephrol Dial Transplant; 2007 Jan; 22(1):284-5. PubMed ID: 16877488
    [No Abstract]   [Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
    Mao Z; Ong AC
    Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc prevents indomethacin-induced renal damage in rats by ameliorating oxidative stress and mitochondrial dysfunction.
    Varghese J; Faith M; Jacob M
    Eur J Pharmacol; 2009 Jul; 614(1-3):114-21. PubMed ID: 19445918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of ZnCl2 in protecting against nephrotoxicity induced by HgCl2 in newborn rats.
    Peixoto NC; Pereira ME
    Ecotoxicol Environ Saf; 2007 Mar; 66(3):441-6. PubMed ID: 16620979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the protective effect of dietary fish oil on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney.
    Priyamvada S; Priyadarshini M; Arivarasu NA; Farooq N; Khan S; Khan SA; Khan MW; Yusufi AN
    Prostaglandins Leukot Essent Fatty Acids; 2008 Jun; 78(6):369-81. PubMed ID: 18556188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of vitamin E and/or quercetin in attenuating chronic cyclosporine A-induced nephrotoxicity in male rats.
    Zal F; Mostafavi-Pour Z; Vessal M
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):720-4. PubMed ID: 17600547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
    Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
    Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of putative genomic biomarkers of nephrotoxicity in rats.
    Wang EJ; Snyder RD; Fielden MR; Smith RJ; Gu YZ
    Toxicology; 2008 Apr; 246(2-3):91-100. PubMed ID: 18289764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secondary nephropathies in occupational health practice. I. Secondary nephropathies due to occupational exposure].
    Antonowicz-Juchniewicz J; Jodkowska A; Kwiecińiska D
    Med Pr; 2006; 57(4):389-400. PubMed ID: 17133921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nonsteroidal antirheumatics and the kidney].
    Galesić K; Morović-Vergles J; Jelaković B
    Reumatizam; 2005; 52(2):61-6. PubMed ID: 16689132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.